UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000012104
Receipt No. R000014143
Scientific Title Japan study of Distal Evaluation of Functional significance of Intra-arterial stenosis Narrowing Effect.
Date of disclosure of the study information 2013/10/22
Last modified on 2016/08/25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Japan study of Distal Evaluation of Functional significance of Intra-arterial stenosis Narrowing Effect.
Acronym Japan study of Distal Evaluation of Functional significance of Intra-arterial stenosis Narrowing Effect.
Scientific Title Japan study of Distal Evaluation of Functional significance of Intra-arterial stenosis Narrowing Effect.
Scientific Title:Acronym Japan study of Distal Evaluation of Functional significance of Intra-arterial stenosis Narrowing Effect.
Region
Japan

Condition
Condition Coronary Artery Disease
Classification by specialty
Cardiology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate whether iFR/FFR guided treatment strategy makes the postulated treatment strategy by CAG guide change and to analyze the cost-effectiveness of its dual diagnosis.

To investigate difference between SYNTAX score evaluated CAG and functional SYNTAX score evaluated physiological assessment of coronary stenosis and its clinical effectiveness.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 1. Primary outcome of medical economy
The cost-effectiveness of iFR/FFR hybrid strategy
2. Primary outcome of physiological assessment
Alteration in treatment protocol
Change in SYNTAX score
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Age>=20 years old.
2. Patient who can understand informed consent of the clinical study and signed the consent.
3. Patient who is adaptable to CAG and/or coronary revascularization
4. Patient who has evaluated stenotic lesion (stenosis>50% in visual judgment) by CAG at main epicardial vessel and its branch or who suspected to have it.
Key exclusion criteria 1. Patient with known contraindications to ATP and/or papaverine hydrochloride
2. Target vessel diameter<=2.0mm
3. Lesion with CTO (registration allowed if other branch has stenosis more than 50% in visual judgment)
4. Patient with temporary/permanent artificial pacemaker implantation, left bundle branch block, second-degree and third-degree atrioventricular block.
5. AMI patient
6. Patient who is disqualified for FFR and coronary revascularization by the investigator.
7. Lesion is disqualified for PCI by the investigator.
8. Patient who has critical valvular disease of heart. (moderate or severe AS/AR/MS/MR)
9. Patient with a prior CABG on target vessel.
10. Patient with severe renal dysfunction. (serum creatinine>=2.0mg/dl)
11. Patient on hemodialysis.
12. Body weight>=200kg
13. Patient who needs ventricular assist device to ensure hemodynamic stability (heart rate<50/min, SBP<90mmHg)
14. Patient who expects to live less than 2 years at the registration
15. Patient with contraindications to an antithrombotic therapy or an anticoagulant therapy.
16. Patient who is poor compliance with drug treatment.
17. Patient who is allergic to contrast agent.
18. LVEF>=30%
19. Patient who has the history of PCI with DES in recent 3 months before registration.
20. Patient who has the history of PCI with BMS or POBA in recent 1 year before registration.
21. Patient who has possibility of pregnancy, under breast-feeding and positive pregnancy test in 14days prior to the PCI.
22. Patients with inadequacy to join this clinical study.
23. Patient who has been enrolled any other clinical study.
Target sample size 500

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Masato Nakamura
Organization Toho University Ohashi Medical Center
Division name Division of Cardiovascular Medicine
Zip code
Address 2-17-6, Ohashi Meguro-ku, Tokyo 153-8515
TEL +81-3-3468-1251
Email masato@oha.toho-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hiroki Takayama
Organization J-DEFINE support center
Division name Soiken Inc.
Zip code
Address NFB Ogawa-cho Bldg 4F, 1-3-1, Kanda Ogawa-cho, Chiyoda-ku, Tokyo 101-0052
TEL 03-3295-1376
Homepage URL
Email info@j-define.org

Sponsor
Institute NPO Associations for Establishment of Evidence in Interventions
Institute
Department

Funding Source
Organization NPO Associations for Establishment of Evidence in Interventions
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2013 Year 10 Month 22 Day

Related information
URL releasing protocol
Publication of results Partially published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2013 Year 10 Month 17 Day
Date of IRB
Anticipated trial start date
2013 Year 10 Month 28 Day
Last follow-up date
2016 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information nonrandomized, open-label, prospective, and multi-center observational study

Management information
Registered date
2013 Year 10 Month 22 Day
Last modified on
2016 Year 08 Month 25 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014143

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.